Zydus Pharmaceuticals USA Inc enters into US$ 5.9 million settlement agreement

ZPUI has agreed to pay a total of US$ 5.9 million to resolve above litigation matters

Zydus Pharmaceuticals USA Inc. (ZPUI), a wholly owned subsidiary of Zydus Lifesciences Limited entered into a settlement agreement with a putative class of Indirect Reseller Plaintiffs to resolve certain litigation matters proceeding as a part of MDL No. 2724 (Case No. 16-md-2724), In re Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania.

Pursuant to the Settlement, ZPUI has agreed to pay a total of US$ 5.9 million to resolve above litigation matters. The Settlement contains a full and final release of all claims by the Indirect Reseller Plaintiffs and was entered into without any admission of fault or wrongdoing by ZPUI.